{"id":528,"date":"2020-09-11T06:35:27","date_gmt":"2020-09-11T06:35:27","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=528"},"modified":"2020-09-11T06:35:27","modified_gmt":"2020-09-11T06:35:27","slug":"08-sep-2020-tocilizumab-effective-in-managing-early-crs-related-to-covid-19-disease","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/08-sep-2020-tocilizumab-effective-in-managing-early-crs-related-to-covid-19-disease\/","title":{"rendered":"(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Tocilizumab for severe COVID-19 related illness &#8211; A community academic medical center experience<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1016\/j.cytox.2020.100035<\/p>\n<p class=\"\">In an academic community medical center,31 patients with anti-IL-6\/IL-6-R agents including 12 who had already been intubated were treated with TCZ. Overall, 27 (87%) patients are alive and 24 (77%) have been discharged from the hospital. Clinical responses to anti-IL-6\/IL-6-R therapy were accompanied by significant decreases in temperature, oxygen requirement, CRP, IL-6, and IL-10 levels. Based on these data, we believe anti-IL-6\/IL-6-R therapy can be effective in managing early CRS related to COVID-19 disease.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab for severe COVID-19 related illness &#8211; A community academic medical center experience https:\/\/doi.org\/10.1016\/j.cytox.2020.100035 In an academic community medical center,31 patients with anti-IL-6\/IL-6-R agents including 12 who had already been intubated were treated with TCZ. Overall, 27 (87%) patients are&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/08-sep-2020-tocilizumab-effective-in-managing-early-crs-related-to-covid-19-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(08 Sep 2020) Tocilizumab- effective in managing early CRS related to COVID-19 disease&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/528"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=528"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/528\/revisions"}],"predecessor-version":[{"id":529,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/528\/revisions\/529"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}